Machine signal
Active cluster sell — 3 distinct insiders, $447.6K, window ends Sep 8, 2026.
Figures computed from official regulatory filings — .
Analysttarget 7.22 USD (+75%) · consensus 3.57/5 · 3 buy · 4 hold · 0 sell
Ownershipinsiders 2.04% · institutions 70.66% · short 35.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for RECURSION PHARMACEUTICALS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
29 buys413 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Dar Zavain | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Li Dean Y | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Taylor Ben R | Other | $18.4K | SEC |
| Khan Najat | Sell | $78.8K | SEC |
| Borgeson Blake | Sell | $100.2K | SEC |
| Taylor Ben R | Other | $79.1K | SEC |
| Khan Najat | Other | $254.4K | Unusual size | SEC |
| Hallett David | Other | $84.2K | SEC |
| Borgeson Blake | Sell | $97.5K | SEC |
| Borgeson Blake | Sell | $158.5K | SEC |
| Dar Zavain | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Li Dean Y | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Li Dean Y | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bumpus Namandje | Sell | $12.6K | SEC |
| Dar Zavain | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERSHBERG ROBERT | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sun Elaine D | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bumpus Namandje | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borgeson Blake | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Michor Franziska | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Taylor Ben R | Other | $17K | SEC |
| Gibson Christopher | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gibson Christopher | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gibson Christopher | Sell | $144.8K | SEC |
| Khan Najat | Sell | $84.5K | SEC |